Results 61 to 70 of about 170,342 (313)

Cross‐Organ Multi‐Omics Profiling of Systemic Alterations in 5xFAD Mice and Changes Associated with Huanglian Jiedu Decoction Treatment

open access: yesAdvanced Science, EarlyView.
Cross‐organ multi‐omics reveals coordinated inflammatory and metabolic disturbances in 5xFAD mice. Huanglian Jiedu Decoction improves cognition and alleviates brain and liver abnormalities. Complementary hepatocyte–microglia conditioned‐medium experiments suggest PPAR‐γ involvement in treatment‐associated changes in microglial inflammation, providing ...
Wenya Gao   +10 more
wiley   +1 more source

Polycystic Ovary Syndrome (PCOS): Insights into Etiology, Genetic, Diagnosis, Treatment, and Future Directions. (A Comprehensive Review) [PDF]

open access: yesمجلة التربية والعلم
In this paper, we obtained the nuclear energy levels for 48Cr isotope that resided in the pf -shell of shell model calculations. For nucleons that were outside closed and no core, they were calculated using skyrme interactions. The Skyrme (SLY5) was used
Lujain Ghannawi   +4 more
doaj   +1 more source

Durable and Additive Disease Control at 52 Weeks With Ixekizumab Plus Tirzepatide Versus Ixekizumab Alone in Adults With Psoriatic Arthritis and Obesity or Overweight: Additional Results From a Randomized Clinical Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective Obesity or overweight occurs in 72% to 82% of individuals with psoriatic arthritis (PsA). Previous data revealed greater disease control with concomitant ixekizumab (IXE) and tirzepatide (TZP) versus IXE alone in adults with active PsA and obesity or overweight with at least one weight‐related comorbidity at the week 36 primary end point. The
Joseph F. Merola   +14 more
wiley   +1 more source

Odd ratio for T2DM and T2DM-NP per 10 ng/mL increase in serum levels of CTRP3.

open access: yes, 2019
Odd ratio for T2DM and T2DM-NP per 10 ng/mL increase in serum levels of CTRP3.
Nariman Moradi (3391952)   +7 more
core   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Sleeve gastrectomy: an ideal choice for T2DM [PDF]

open access: yesNature Reviews Endocrinology, 2013
As Ricardo Cohen pointed out (Sleeve gastrectomy: the ideal option for meta‐ bolic surgery? Nat. Rev. Endocrinol. 9, doi:10.1038/nrendo.2013.100‐c1)1 concern‐ ing my News and Views article (Sleeve gas‐ trectomy—the ideal choice for weight‐loss surgery. Nat. Rev. Endocrinol.
openaire   +2 more sources

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić   +7 more
wiley   +1 more source

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić   +8 more
wiley   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad   +4 more
wiley   +1 more source

Comparison of Imaging features of T2DM MDR-TB, T2DM DS-TB and pure DS-TB cases.

open access: yes, 2016
Comparison of Imaging features of T2DM MDR-TB, T2DM DS-TB and pure DS-TB cases.
Guoqing Zhang (151441)   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy